NasdaqGS:PODD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. More Details


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Insulet's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PODD has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.0%

PODD

-0.2%

US Medical Equipment

-0.7%

US Market


1 Year Return

61.4%

PODD

24.1%

US Medical Equipment

19.9%

US Market

Return vs Industry: PODD exceeded the US Medical Equipment industry which returned 24.1% over the past year.

Return vs Market: PODD exceeded the US Market which returned 19.9% over the past year.


Shareholder returns

PODDIndustryMarket
7 Day1.0%-0.2%-0.7%
30 Day10.4%5.9%5.8%
90 Day22.7%9.2%8.3%
1 Year61.4%61.4%25.1%24.1%22.7%19.9%
3 Year307.0%307.0%76.8%72.2%43.5%33.9%
5 Year731.4%731.4%155.7%135.6%86.9%65.8%

Price Volatility Vs. Market

How volatile is Insulet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Insulet undervalued compared to its fair value and its price relative to the market?

858.96x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PODD ($248.33) is trading above our estimate of fair value ($151.46)

Significantly Below Fair Value: PODD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PODD is poor value based on its PE Ratio (859x) compared to the US Medical Equipment industry average (51.1x).

PE vs Market: PODD is poor value based on its PE Ratio (859x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: PODD is poor value based on its PEG Ratio (17.7x)


Price to Book Ratio

PB vs Industry: PODD is overvalued based on its PB Ratio (28.9x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

48.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PODD's forecast earnings growth (48.6% per year) is above the savings rate (2.2%).

Earnings vs Market: PODD's earnings (48.6% per year) are forecast to grow faster than the US market (22.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PODD's revenue (17.3% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: PODD's revenue (17.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PODD's Return on Equity is forecast to be low in 3 years time (15.9%).


Next Steps

Past Performance

How has Insulet performed over the past 5 years?

58.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PODD has a large one-off loss of $8.7M impacting its June 30 2020 financial results.

Growing Profit Margin: PODD's current net profit margins (2.2%) are lower than last year (2.7%).


Past Earnings Growth Analysis

Earnings Trend: PODD has become profitable over the past 5 years, growing earnings by 58% per year.

Accelerating Growth: PODD's earnings growth over the past year (4.3%) is below its 5-year average (58% per year).

Earnings vs Industry: PODD earnings growth over the past year (4.3%) exceeded the Medical Equipment industry 2.5%.


Return on Equity

High ROE: PODD's Return on Equity (3.2%) is considered low.


Next Steps

Financial Health

How is Insulet's financial position?


Financial Position Analysis

Short Term Liabilities: PODD's short term assets ($1.1B) exceed its short term liabilities ($134.4M).

Long Term Liabilities: PODD's short term assets ($1.1B) exceed its long term liabilities ($929.0M).


Debt to Equity History and Analysis

Debt Level: PODD's debt to equity ratio (158.4%) is considered high.

Reducing Debt: PODD's debt to equity ratio has reduced from 250.4% to 158.4% over the past 5 years.

Debt Coverage: PODD's debt is not well covered by operating cash flow (11.3%).

Interest Coverage: PODD's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Insulet current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PODD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PODD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PODD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PODD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PODD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Shacey Petrovic (46 yo)

1.75yrs

Tenure

US$5,883,985

Compensation

Ms. Shacey Petrovic has been Director at Exact Sciences Corporation since July 22, 2020. Ms. Petrovic serves as Director of Alydia Health, Inc. She is the President of Insulet Corporation since October, 20 ...


CEO Compensation Analysis

Compensation vs Market: Shacey's total compensation ($USD5.88M) is below average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Shacey's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shacey Petrovic
President1.75yrsUS$5.88m0.14%
$ 22.1m
Wayde McMillan
Executive VP1.58yrsUS$4.47m0.0082%
$ 1.3m
Charles Alpuche
Executive VP & COO1.75yrsUS$3.35m0.042%
$ 6.9m
John Kapples
Senior VP1.58yrsUS$2.25m0.0053%
$ 867.3k
Bret Christensen
Executive VP & Chief Commercial Officer3.42yrsUS$2.32m0.012%
$ 1.9m
Michael Levitz
1.58yrsUS$1.06m0.079%
$ 12.9m
Lauren Budden
VP, Chief Accounting Officer & Controller1.5yrsno data0.0018%
$ 286.9k
Deborah Gordon
Vice President of Investor Relations5.75yrsno datano data
Michael Spears
Senior Vice President of Quality and Regulatory Affairs & Compliance3.67yrsUS$1.54m0.0081%
$ 1.3m
Philip Hildale
Senior Vice President of Sales & Customer Care5.75yrsno datano data
Christopher Gilbert
Vice President of Marketing5.75yrsno datano data
Dan Manea
Senior VP & Chief Human Resources Officer0.42yrno datano data

1.8yrs

Average Tenure

50yo

Average Age

Experienced Management: PODD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Shacey Petrovic
President1.75yrsUS$5.88m0.14%
$ 22.1m
Sally Crawford
Independent Director12yrsUS$243.25k0.043%
$ 7.1m
Timothy Scannell
Independent Chairman1.75yrsUS$268.75k0.034%
$ 5.6m
Robert Sherwin
Chairman of Scientific Advisory Boardno datano datano data
Howard Wolpert
Member of Scientific Advisory Boardno datano datano data
Margaret Lawlor
Member of Educator Advisory Boardno datano datano data
Camille Izlar
Member of Educator Advisory Boardno datano datano data
Mary Halvorson
Member of Educator Advisory Boardno datano datano data
Steven Edelman
Member of Scientific Advisory Boardno datano datano data
Anne Daly
Member of Educator Advisory Boardno datano datano data
Corinne Nevinny
Independent Director1.75yrsUS$482.84k0.0025%
$ 412.5k
Jessica Hopfield
Lead Independent Director4.17yrsUS$241.61k0.033%
$ 5.4m

2.1yrs

Average Tenure

57.5yo

Average Age

Experienced Board: PODD's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PODD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.


Top Shareholders

Company Information

Insulet Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Insulet Corporation
  • Ticker: PODD
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.303b
  • Shares outstanding: 65.65m
  • Website: https://www.insulet.com

Number of Employees


Location

  • Insulet Corporation
  • 100 Nagog Park
  • Acton
  • Massachusetts
  • 1720
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PODDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2007
GOVDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2007

Biography

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnip ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/19 06:13
End of Day Share Price2020/10/16 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.